Anthelmintic avermectins kill mycobacterium tuberculosis, including multidrug-resistant clinical strains

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 1040-1046

  Lim, Leah E ^a   Vilchèze, Catherine ^b   Ng, Carol ^a   Jacobs, William R ^a,b   Ramón García, Santiago ^a   Thompson, Charles J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVERMECTIN; DORAMECTIN; IVERMECTIN; MOXIDECTIN; SELAMECTIN;

ANTHELMINTIC ACTIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; DRUG SAFETY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL;

ANTHELMINTICS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; IVERMECTIN; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84872842061     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01696-12     Document Type: Article

References (27)

1. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6:29-40.
2. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. 2011. The challenge of new drug discovery for tuberculosis. Nature 469:483-490.
3. Chong CR, Sullivan DJ, Jr. 2007. New uses for old drugs. Nature 448: 645-646.
4. Ramon-Garcia S, Ng C, Anderson H, Chao JD, Zheng X, Pfeifer T, Av-Gay Y, Roberge M, Thompson CJ. 2011. Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. Antimicrob. Agents Chemother. 55:3861-3869.
5. Omura S, Crump A. 2004. The life and times of ivermectin-a success story. Nat. Rev. Microbiol. 2:984-989.
6. Burg RW, Miller BM, Baker EE, Birnbaum J, Currie SA, Hartman R, Kong YL, Monaghan RL, Olson G, Putter I, Tunac JB, Wallick H, Stapley EO, Oiwa R, Omura S. 1979. Avermectins, new family of potent anthelmintic agents: Producing organism and fermentation. Antimicrob. Agents Chemother. 15:361-367.
7. Campbell WC. 1985. Ivermectin: An update. Parasitol. Today 1:10-16.
8. Hotson IK. 1982. The avermectins: A new family of antiparasitic agents. J. S. Afr. Vet. Assoc. 53:87-90.
9. Nagai K, Shiomi K, Sunazuka T, Harder A, Turberg A, Omura S. 2004. Synthesis and biological evaluation of novel 4?-alkoxy avermectin derivatives. Bioorg. Med. Chem. Lett. 14:4135-4139.
10. Ioerger TR, Koo S, No EG, Chen X, Larsen MH, Jacobs WR, Jr, Pillay M, Sturm AW, Sacchettini JC. 2009. Genome analysis of multi-and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South Africa. PLoS One 4:e7778. doi:10.1371/journal.pone.0007778.
11. Morris RP, Nguyen L, Gatfield J, Visconti K, Nguyen K, Schnappinger D, Ehrt S, Liu Y, Heifets L, Pieters J, Schoolnik G, Thompson CJ. 2005. Ancestral antibiotic resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 102:12200-12205.
12. Montoro E, Lemus D, Echemendia M, Martin A, Portaels F, Palomino JC. 2005. Comparative evaluation of the nitrate reduction assay, the MTT test, and the resazurin microtitre assay for drug susceptibility testing of clinical isolates of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 55:500-505.
13. Gomez-Flores R, Gupta S, Tamez-Guerra R, Mehta RT. 1995. Determination of MICs for Mycobacterium avium-M. intracellulare complex in liquid medium by a colorimetric method. J. Clin. Microbiol. 33:1842-1846.
14. Foongladda S, Roengsanthia D, Arjrattanakool W, Chuchottaworn C, Chaiprasert A, Franzblau SG. 2002. Rapid and simple MTT method for rifampicin and isoniazid susceptibility testing of Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 6:1118-1122.
15. Pethe K, Sequeira PC, Agarwalla S, Rhee K, Kuhen K, Phong WY, Patel V, Beer D, Walker JR, Duraiswamy J, Jiricek J, Keller TH, Chatterjee A, Tan MP, Ujjini M, Rao SP, Camacho L, Bifani P, Mak PA, Ma I, Barnes SW, Chen Z, Plouffe D, Thayalan P, Ng SH, Au M, Lee BH, Tan BH, Ravindran S, Nanjundappa M, Lin X, Goh A, Lakshminarayana SB, Shoen C, Cynamon M, Kreiswirth B, Dartois V, Peters EC, Glynne R, Brenner S, Dick T. 2010. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat. Commun. 1:57.
16. Stanley SA, Grant SS, Kawate T, Iwase N, Shimizu M, Wivagg C, Silvis M, Kazyanskaya E, Aquadro J, Golas A, Fitzgerald M, Dai H, Zhang L, Hung DT. 2012. Identification of novel inhibitors of M. tuberculosis growth using whole-cell based high-throughput screening. ACS Chem. Biol. 7:1377-1384. Reference deleted.
17. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil RK, Kantharaj E, Balasubramanian V. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47: 2118-2124.
18. Geary TG. 2005. Ivermectin 20 years on: Maturation of a wonder drug. Trends Parasitol. 21:530-532.
19. Merck & Co., Inc. 2007. Stromectol (ivermectin) package insert NDA 50-742/S-022. Merck & Co., Inc., Whitehouse Station, NJ.
20. Taylor MJ, Hoerauf A, Bockarie M. 2010. Lymphatic filariasis and onchocerciasis. Lancet 376:1175-1185.
21. McKellar QA, Gokbulut C. 2012. Pharmacokinetic features of the antiparasitic macrocyclic lactones. Curr. Pharm. Biotechnol. 13:888-911.
22. Cotreau MM, Warren S, Ryan JL, Fleckenstein L, Vanapalli SR, Brown KR, Rock D, Chen CY, Schwertschlag US. 2003. The antiparasitic moxidectin: Safety, tolerability, and pharmacokinetics in humans. J. Clin. Pharmacol. 43:1108-1115.
23. Merck & Co., Inc. 2011. Merck corporate responsibility report. Mectizan donation program. Merck & Co., Inc., Whitehouse Station, NJ.
24. Global Alliance for TB Drug Development. 2008. Handbook of antituberculosis agents. Tuberculosis (Edinb.) 88:85-170.
25. Chatterjee D. 1997. The mycobacterial cell wall: Structure, biosynthesis and sites of drug action. Curr. Opin. Chem. Biol. 1:579-588.
26. Wolstenholme AJ, Rogers AT. 2005. Glutamate-gated chloride channels and the mode of action of the avermectin/milbemycin anthelmintics. Parasitology 131:S85-S95.
27. Gonzalez Canga A, Sahagun Prieto AM, Diez Liebana MJ, Fernandez Martinez N, Sierra Vega M, Garcia Vieitez JJ. 2008. The pharmacokinetics and interactions of ivermectin inhumans-amini-review.AAPSJ. 10:42-46.